Pharmacologic Treatment of Perinatal Depression

Mary C. Kimmel; Elizabeth Cox; Crystal Schiller; Edith Gettes; Samantha Meltzer-Brody

doi:10.1016/j.ogc.2018.04.007

Pharmacologic Treatment of Perinatal Depression

Mary C. Kimmel, Elizabeth Cox, Crystal Schiller, Edith Gettes, Samantha Meltzer-Brody

Division of Child & Adolescent Psychiatry

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

This review provides information about medications used to treat perinatal depression, including guidance around when to use certain medications and when to consult a mental health provider. For each group of medications, including selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, mirtazapine, bupropion, lithium, atypical antipsychotics, and lamotrigine, the risks and benefits of treatment during pregnancy and lactation are reviewed, and unique qualities of each medication. A treatment algorithm is included and a description of the Food and Drug Administration's approach to providing information about medications. The article also discusses hormone therapies and future directions for new pharmacologic treatments.

Original language	English
Pages (from-to)	419-440
Number of pages	22
Journal	Obstetrics and Gynecology Clinics of North America
Volume	45
Issue number	3
DOIs	https://doi.org/10.1016/j.ogc.2018.04.007
State	Published - Sep 2018

Keywords

Depression
Medication
Mental health
Peripartum
Treatment considerations

Access to Document

10.1016/j.ogc.2018.04.007

Cite this

@article{691655b8040d409c992aa9fdb50ed663,

title = "Pharmacologic Treatment of Perinatal Depression",

abstract = "This review provides information about medications used to treat perinatal depression, including guidance around when to use certain medications and when to consult a mental health provider. For each group of medications, including selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, mirtazapine, bupropion, lithium, atypical antipsychotics, and lamotrigine, the risks and benefits of treatment during pregnancy and lactation are reviewed, and unique qualities of each medication. A treatment algorithm is included and a description of the Food and Drug Administration's approach to providing information about medications. The article also discusses hormone therapies and future directions for new pharmacologic treatments.",

keywords = "Depression, Medication, Mental health, Peripartum, Treatment considerations",

author = "Kimmel, {Mary C.} and Elizabeth Cox and Crystal Schiller and Edith Gettes and Samantha Meltzer-Brody",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = sep,

doi = "10.1016/j.ogc.2018.04.007",

language = "English",

volume = "45",

pages = "419--440",

journal = "Obstetrics and Gynecology Clinics of North America",

issn = "0889-8545",

number = "3",

}

TY - JOUR

T1 - Pharmacologic Treatment of Perinatal Depression

AU - Kimmel, Mary C.

AU - Cox, Elizabeth

AU - Schiller, Crystal

AU - Gettes, Edith

AU - Meltzer-Brody, Samantha

PY - 2018/9

Y1 - 2018/9

N2 - This review provides information about medications used to treat perinatal depression, including guidance around when to use certain medications and when to consult a mental health provider. For each group of medications, including selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, mirtazapine, bupropion, lithium, atypical antipsychotics, and lamotrigine, the risks and benefits of treatment during pregnancy and lactation are reviewed, and unique qualities of each medication. A treatment algorithm is included and a description of the Food and Drug Administration's approach to providing information about medications. The article also discusses hormone therapies and future directions for new pharmacologic treatments.

AB - This review provides information about medications used to treat perinatal depression, including guidance around when to use certain medications and when to consult a mental health provider. For each group of medications, including selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, mirtazapine, bupropion, lithium, atypical antipsychotics, and lamotrigine, the risks and benefits of treatment during pregnancy and lactation are reviewed, and unique qualities of each medication. A treatment algorithm is included and a description of the Food and Drug Administration's approach to providing information about medications. The article also discusses hormone therapies and future directions for new pharmacologic treatments.

KW - Depression

KW - Medication

KW - Mental health

KW - Peripartum

KW - Treatment considerations

UR - http://www.scopus.com/inward/record.url?scp=85051024940&partnerID=8YFLogxK

U2 - 10.1016/j.ogc.2018.04.007

DO - 10.1016/j.ogc.2018.04.007

M3 - Review article

C2 - 30092919

AN - SCOPUS:85051024940

SN - 0889-8545

VL - 45

SP - 419

EP - 440

JO - Obstetrics and Gynecology Clinics of North America

JF - Obstetrics and Gynecology Clinics of North America

IS - 3

ER -

Pharmacologic Treatment of Perinatal Depression

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this